Passionately creating medicines that make a difference requires insights through close collaboration with patients and patient organizations.
Patient insights
UNION’s vision is to passionately create medicines that make a difference. We interact with individual patients and patient organizations to better understand the unmet medical needs among patients and to get insights that are important for our work with both pharmaceutical innovation, for example in relation to drug delivery and ease-of-use of the drug supporting patient adherence, and clinical development, for example with respect to endpoints and the use of quality-of-life metrics in clinical studies.
Engaging with patients and raising awareness
We are committed to develop safe and effective medicines that can help improve quality of life among patients suffering from immunological diseases. These include patients living with atopic dermatitis, hidradenitis suppurativa, psoriasis and ulcerative colitis. We acknowledge the important role that patient organizations have in raising awareness about disease and treatment.
Our engagement with patient organizations thus serves different purposes:
- Building a deep understanding of the unmet medical needs among patients
- Getting insights and advice from patients on both pharmaceutical innovation and clinical development
- Raising awareness about the burden of disease, for example through patient stories, campaigns, and other disease awareness activities
Transparency in our interactions with patient organizations
UNION wants to help patient organizations speak up about the burden of disease and is a member of the following patient organizations:
Eksemforeningen, membership fee 2023: DKK 2.500.
Patientforeningen HS Danmark, membership fee 2023: DKK 1.500.
Psoriasisforeningen Denmark, membership fee 2023: DKK 7.900.
Colitis-Crohn Foreningen, membership fee 2023: DKK 2.000.
Making a difference for patients
As part of UNION’s market access and affordability strategy, the company is committed to:
- Exploring opportunities by initiating expanded access programs in which UNION could provide patients with access to UNION’s investigational products through long-term clinical trials.
- Evaluating responsible pricing approaches to provide underserved patient populations with access to UNION’s products when being approved and launched.
- Establishing and strengthening UNION’s collaborations with regional and global
patient organizations to support research activities and enhance disease awareness among healthcare professionals and patient communities.
